Literature DB >> 17609305

Thyroid echogenicity predicts outcome of radioiodine therapy in patients with Graves' disease.

Vinko Markovic1, Davor Eterovic.   

Abstract

CONTEXT: Despite accounting for variations in gland size and iodine kinetics, the success of radioiodine therapy in patients with Graves' disease remains moderately common and unpredictable.
OBJECTIVES: We hypothesized that hypoechogenic glands, with large, densely packed cells, are more radiosensitive than normoechogenic glands, in which much radiation is wasted on more abundant colloid. We evaluated this hypothesis in a cohort of patients with Graves' disease.
DESIGN: This was a prospective trial of patients recruited during 4 yr and followed up 1 yr after radioiodine therapy.
SETTING: This trial was held in a university hospital-outpatient clinic. PATIENTS: A total of 177 consecutive patients with first presentation of Graves' disease (28 males), 23-76 yr old, who relapsed after antithyroid therapy were included in the study. INTERVENTION: The patients were assigned to an ablative target-absorbed dose of 200 Gy (n = 78) or randomly to 100 or 120 Gy of nonablative dose (n = 99). MAIN OUTCOME MEASURES: The measures were incidences of hyperthyroidism, euthyroidism, and hypothyroidism at 12-month follow-up.
RESULTS: At follow-up there were 25 hyperthyroid, 44 euthyroid, and 108 hypothyroid patients. Compared with 96 patients with a hypoechogenic gland, in 81 patients with a normoechogenic gland, there were more hyperthyroid (22 vs. 7%) and euthyroid (41 vs. 11%), but less hypothyroid outcomes (37 vs. 81%; P < 0.0001). The other independent predictor of increased radioresistance was the large gland volume.
CONCLUSION: In patients with Graves' disease, normoechogenic and large glands are associated with increased radioresistance.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17609305     DOI: 10.1210/jc.2007-0879

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

1.  Determinants of 131I radiation dose to thyroid follicular cells.

Authors:  Davor Eterović; Vinko Marković; Zeljko Antunović; Ante Punda
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-02-20       Impact factor: 9.236

2.  Role of color Doppler in differentiation of Graves' disease and thyroiditis in thyrotoxicosis.

Authors:  Ragab Hani Donkol; Aml Mohamed Nada; Sami Boughattas
Journal:  World J Radiol       Date:  2013-04-28

3.  Radiometabolic treatment of hyperthyroidism with a calculated dose of 131-iodine: results of one-year follow-up.

Authors:  C Regalbuto; I Marturano; A Condorelli; A Latina; V Pezzino
Journal:  J Endocrinol Invest       Date:  2009-02       Impact factor: 4.256

4.  Duplex Hemodynamic Parameters of Both Superior and Inferior Thyroid Arteries in Evaluation of Thyroid Hyperfunction Disorders.

Authors:  Maha Assem Hussein; Alaa Abdel Hamid; Rasha M Abdel Samie; Elshaymaa Hussein; Shereen Sadik Elsawy
Journal:  Int J Gen Med       Date:  2022-09-09

5.  Extremely high doses of radioiodine required for treatment of Graves' hyperthyroidism: a case report.

Authors:  Arnaldo Moura Neto; Marcos Antonio Tambascia; Sergio Brunetto; Celso Dario Ramos; Denise Engelbrecht Zantut-Wittmann
Journal:  Cases J       Date:  2009-08-25

6.  Predictors of euthyreosis in hyperthyroid patients treated with radioiodine 131I-: a retrospective study.

Authors:  Albert Stachura; Tomasz Gryn; Bernadetta Kałuża; Tadeusz Budlewski; Edward Franek
Journal:  BMC Endocr Disord       Date:  2020-06-01       Impact factor: 2.763

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.